Observational studyCirculation2022
Impact of Earlier Diagnosis in Cardiac ATTR Amyloidosis Over the Course of 20 Years.
Registry-linked trialOpen access · bronzeAbstract readObservational Study
In one paragraph
Observational study in Circulation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07529860 (AI-based Echocardiography for Detection of Cardiac Amyloidosis in Patients Undergoing Transthoracic Echocardiography With Left Ventricular Hypertrophy), which is not on this map. Cited by 123 papers, 5 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
123citing papers in PubMed, 5 pooled it
16.8field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
AI-based Echocardiography for Detection of Cardiac Amyloidosis in Patients Undergoing Transthoracic Echocardiography With Left Ventricular Hypertrophy
Who cites it
123 citing papers in PubMed, 5 syntheses or guidelines pooled it, 212 citations in OpenAlex.
- Real-world effectiveness of targeted therapies in ATTR cardiomyopathy: A meta-analysis integrating population-based data.ESC heart failure · 2025Pooled it
- Pooled it
- Sodium-glucose cotransporter 2 inhibitors and outcomes in transthyretin amyloid cardiomyopathy: Systematic review and meta-analysis.European journal of clinical investigation · 2025Pooled it
- Epidemiology of transthyretin (ATTR) amyloidosis: a systematic literature review.Orphanet journal of rare diseases · 2025Pooled it
- Disease-Modifying Therapies for Transthyretin Amyloid Cardiomyopathy: A Systematic Review and Meta-Analysis.Arquivos brasileiros de cardiologia · 2025Pooled it
- Vutrisiran-Mediated Knockdown of Transthyretin in Patients with ATTR Amyloidosis.Clinical pharmacokinetics · 2026Trial
- Rationale and Design of CARDIO-TTRansform, a Phase 3 Trial of Eplontersen in Transthyretin Amyloid Cardiomyopathy.Circulation. Heart failure · 2026Trial
- Effects of vutrisiran on cardiac structure and function in patients with transthyretin amyloidosis with cardiomyopathy: secondary outcomes of the HELIOS-B trial.Nature medicine · 2025Trial
- Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis.The New England journal of medicine · 2023Trial
- Amyloid Transthyretin Cardiomyopathy in Elderly Patients With Aortic Stenosis Undergoing Transcatheter Aortic Valve Implantation.Journal of the American Heart Association · 2023Trial
- Proteomics Profiling Reveals Molecular Subtypes of Transthyretin Cardiac Amyloidosis.Circulation. Heart failure · 2026Article
- Regional Myocardial Tissue Characterization by Cardiac Magnetic Resonance Is Associated With Heart Failure Development in Asymptomatic Transthyretin Amyloid Cardiomyopathy.Circulation reports · 2026Article
- Rationale and Design of ACO-REAL: A Real-World Non-Interventional Study of Acoramidis in Routine Clinical Practice.Cardiology and therapy · 2026Article
- Contemporary real-world treatment of cardiac transthyretin amyloidosis with tafamidis: a long-term multicentre study.ESC heart failure · 2026Article
- Patient Characteristics and Diagnosis of Transthyretin Amyloid Cardiomyopathy in Japan: Baseline Analysis of J-COSSA.JACC. Asia · 2026Article
- Overcoming barriers to early diagnosis and treatment of p.Val142Ile amyloid transthyretin (ATTR) cardiomyopathy.Heart failure reviews · 2026Review
- Cardio amyloid-artificial intelligence: advanced multi-modal screening for transthyretin cardiac amyloidosis in severe aortic stenosis patients.European heart journal. Digital health · 2026Article
- Cliramitug for depletion of cardiac amyloid transthyretin: long-term follow-up of the NI006-101 trial.Nature medicine · 2026Article
- Biologics for cardiovascular diseases: from bench to bedside.Signal transduction and targeted therapy · 2026Review
- Pathways for Patients with Transthyretin Amyloid Cardiomyopathy from a District General Hospital Perspective.Journal of cardiovascular development and disease · 2026Article
63 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
27 authors at 7 institutions in 3 countries.
Adam Ioannou *National Amyloidosis Centre, University College London, Royal Free Campus, United Kingdom (A.I., R.K.P., Y.R., A. Porcari, L.V., A.M., G.E.W., S.O., S.G., P.M., D.K., A.M.-N., T.K., L.C., J.B., M.U.R., H.L., A.W., A. Petrie, C.W., P.N.H., J.D.G., M.F.).ORCID 0000-0001-5017-8657
Rishi K Patel *National Amyloidosis Centre, University College London, Royal Free Campus, United Kingdom (A.I., R.K.P., Y.R., A. Porcari, L.V., A.M., G.E.W., S.O., S.G., P.M., D.K., A.M.-N., T.K., L.C., J.B., M.U.R., H.L., A.W., A. Petrie, C.W., P.N.H., J.D.G., M.F.).ORCID 0000-0002-3177-5680
Yousuf RazviNational Amyloidosis Centre, University College London, Royal Free Campus, United Kingdom (A.I., R.K.P., Y.R., A. Porcari, L.V., A.M., G.E.W., S.O., S.G., P.M., D.K., A.M.-N., T.K., L.C., J.B., M.U.R., H.L., A.W., A. Petrie, C.W., P.N.H., J.D.G., M.F.).
Aldostefano PorcariNational Amyloidosis Centre, University College London, Royal Free Campus, United Kingdom (A.I., R.K.P., Y.R., A. Porcari, L.V., A.M., G.E.W., S.O., S.G., P.M., D.K., A.M.-N., T.K., L.C., J.B., M.U.R., H.L., A.W., A. Petrie, C.W., P.N.H., J.D.G., M.F.).ORCID 0000-0003-3307-0825
Gianfranco SinagraCenter for Diagnosis and Treatment of Cardiomyopathies, Cardiovascular Department, Azienda Sanitaria Universitaria Giuliano-Isontina, University of Trieste, Italy (A. Porcari, G.S.).ORCID 0000-0003-2700-8478
Lucia VenneriNational Amyloidosis Centre, University College London, Royal Free Campus, United Kingdom (A.I., R.K.P., Y.R., A. Porcari, L.V., A.M., G.E.W., S.O., S.G., P.M., D.K., A.M.-N., T.K., L.C., J.B., M.U.R., H.L., A.W., A. Petrie, C.W., P.N.H., J.D.G., M.F.).
Francesco BanderaCardiology University Department, IRCCS Policlinico San Donato, Milan, Italy (F.B.).
Ambra MasiNational Amyloidosis Centre, University College London, Royal Free Campus, United Kingdom (A.I., R.K.P., Y.R., A. Porcari, L.V., A.M., G.E.W., S.O., S.G., P.M., D.K., A.M.-N., T.K., L.C., J.B., M.U.R., H.L., A.W., A. Petrie, C.W., P.N.H., J.D.G., M.F.).ORCID 0000-0003-0535-1187
Georgina E WilliamsNational Amyloidosis Centre, University College London, Royal Free Campus, United Kingdom (A.I., R.K.P., Y.R., A. Porcari, L.V., A.M., G.E.W., S.O., S.G., P.M., D.K., A.M.-N., T.K., L.C., J.B., M.U.R., H.L., A.W., A. Petrie, C.W., P.N.H., J.D.G., M.F.).
Sophie O'BearaNational Amyloidosis Centre, University College London, Royal Free Campus, United Kingdom (A.I., R.K.P., Y.R., A. Porcari, L.V., A.M., G.E.W., S.O., S.G., P.M., D.K., A.M.-N., T.K., L.C., J.B., M.U.R., H.L., A.W., A. Petrie, C.W., P.N.H., J.D.G., M.F.).ORCID 0000-0001-8772-1502
Sharmananthan GanesananthanNational Amyloidosis Centre, University College London, Royal Free Campus, United Kingdom (A.I., R.K.P., Y.R., A. Porcari, L.V., A.M., G.E.W., S.O., S.G., P.M., D.K., A.M.-N., T.K., L.C., J.B., M.U.R., H.L., A.W., A. Petrie, C.W., P.N.H., J.D.G., M.F.).ORCID 0000-0002-2300-7008
Paolo MassaNational Amyloidosis Centre, University College London, Royal Free Campus, United Kingdom (A.I., R.K.P., Y.R., A. Porcari, L.V., A.M., G.E.W., S.O., S.G., P.M., D.K., A.M.-N., T.K., L.C., J.B., M.U.R., H.L., A.W., A. Petrie, C.W., P.N.H., J.D.G., M.F.).
Daniel KnightNational Amyloidosis Centre, University College London, Royal Free Campus, United Kingdom (A.I., R.K.P., Y.R., A. Porcari, L.V., A.M., G.E.W., S.O., S.G., P.M., D.K., A.M.-N., T.K., L.C., J.B., M.U.R., H.L., A.W., A. Petrie, C.W., P.N.H., J.D.G., M.F.).ORCID 0000-0002-0512-3961
Ana Martinez-NaharroNational Amyloidosis Centre, University College London, Royal Free Campus, United Kingdom (A.I., R.K.P., Y.R., A. Porcari, L.V., A.M., G.E.W., S.O., S.G., P.M., D.K., A.M.-N., T.K., L.C., J.B., M.U.R., H.L., A.W., A. Petrie, C.W., P.N.H., J.D.G., M.F.).
Tushar KotechaNational Amyloidosis Centre, University College London, Royal Free Campus, United Kingdom (A.I., R.K.P., Y.R., A. Porcari, L.V., A.M., G.E.W., S.O., S.G., P.M., D.K., A.M.-N., T.K., L.C., J.B., M.U.R., H.L., A.W., A. Petrie, C.W., P.N.H., J.D.G., M.F.).ORCID 0000-0003-0059-4817
Liza ChackoNational Amyloidosis Centre, University College London, Royal Free Campus, United Kingdom (A.I., R.K.P., Y.R., A. Porcari, L.V., A.M., G.E.W., S.O., S.G., P.M., D.K., A.M.-N., T.K., L.C., J.B., M.U.R., H.L., A.W., A. Petrie, C.W., P.N.H., J.D.G., M.F.).
James BrownNational Amyloidosis Centre, University College London, Royal Free Campus, United Kingdom (A.I., R.K.P., Y.R., A. Porcari, L.V., A.M., G.E.W., S.O., S.G., P.M., D.K., A.M.-N., T.K., L.C., J.B., M.U.R., H.L., A.W., A. Petrie, C.W., P.N.H., J.D.G., M.F.).ORCID 0000-0003-1541-4081
Muhammad U RaufNational Amyloidosis Centre, University College London, Royal Free Campus, United Kingdom (A.I., R.K.P., Y.R., A. Porcari, L.V., A.M., G.E.W., S.O., S.G., P.M., D.K., A.M.-N., T.K., L.C., J.B., M.U.R., H.L., A.W., A. Petrie, C.W., P.N.H., J.D.G., M.F.).ORCID 0000-0001-8793-9333
Charlotte ManistySt Bartholomew's Hospital, London, United Kingdom (C.M., J.M.).ORCID 0000-0003-0245-7090
James MoonSt Bartholomew's Hospital, London, United Kingdom (C.M., J.M.).
Helen LachmannNational Amyloidosis Centre, University College London, Royal Free Campus, United Kingdom (A.I., R.K.P., Y.R., A. Porcari, L.V., A.M., G.E.W., S.O., S.G., P.M., D.K., A.M.-N., T.K., L.C., J.B., M.U.R., H.L., A.W., A. Petrie, C.W., P.N.H., J.D.G., M.F.).
Ashutosh WechelakarNational Amyloidosis Centre, University College London, Royal Free Campus, United Kingdom (A.I., R.K.P., Y.R., A. Porcari, L.V., A.M., G.E.W., S.O., S.G., P.M., D.K., A.M.-N., T.K., L.C., J.B., M.U.R., H.L., A.W., A. Petrie, C.W., P.N.H., J.D.G., M.F.).
Aviva PetrieNational Amyloidosis Centre, University College London, Royal Free Campus, United Kingdom (A.I., R.K.P., Y.R., A. Porcari, L.V., A.M., G.E.W., S.O., S.G., P.M., D.K., A.M.-N., T.K., L.C., J.B., M.U.R., H.L., A.W., A. Petrie, C.W., P.N.H., J.D.G., M.F.).ORCID 0000-0002-5236-4741
Carol WhelanNational Amyloidosis Centre, University College London, Royal Free Campus, United Kingdom (A.I., R.K.P., Y.R., A. Porcari, L.V., A.M., G.E.W., S.O., S.G., P.M., D.K., A.M.-N., T.K., L.C., J.B., M.U.R., H.L., A.W., A. Petrie, C.W., P.N.H., J.D.G., M.F.).
Philip N HawkinsNational Amyloidosis Centre, University College London, Royal Free Campus, United Kingdom (A.I., R.K.P., Y.R., A. Porcari, L.V., A.M., G.E.W., S.O., S.G., P.M., D.K., A.M.-N., T.K., L.C., J.B., M.U.R., H.L., A.W., A. Petrie, C.W., P.N.H., J.D.G., M.F.).
Julian D Gillmore *National Amyloidosis Centre, University College London, Royal Free Campus, United Kingdom (A.I., R.K.P., Y.R., A. Porcari, L.V., A.M., G.E.W., S.O., S.G., P.M., D.K., A.M.-N., T.K., L.C., J.B., M.U.R., H.L., A.W., A. Petrie, C.W., P.N.H., J.D.G., M.F.).ORCID 0000-0001-6174-9232
Marianna Fontana *National Amyloidosis Centre, University College London, Royal Free Campus, United Kingdom (A.I., R.K.P., Y.R., A. Porcari, L.V., A.M., G.E.W., S.O., S.G., P.M., D.K., A.M.-N., T.K., L.C., J.B., M.U.R., H.L., A.W., A. Petrie, C.W., P.N.H., J.D.G., M.F.).ORCID 0000-0002-9233-9831
MACOM (United States) · USRoyal Society · GBSt Bartholomew's Hospital · GBAzienda Sanitaria Universitaria Integrata di Trieste · ITEngineering and Physical Sciences Research Council · GBIRCCS Policlinico San Donato · ITUnited States Nuclear Regulatory Commission · US
Funding
British Heart Foundation FS/18/21/33447British Heart Foundation FS/CRLF/20/23004
Abstract
backgroundDiagnostic and therapeutic advances have led to much greater awareness of transthyretin cardiac amyloidosis (ATTR-CA). We aimed to characterize changes in the clinical phenotype of patients diagnosed with ATTR-CA over the past 20 years.
methodsThis is a retrospective observational cohort study of all patients referred to the National Amyloidosis Centre (2002-2021) in whom ATTR-CA was a differential diagnosis.
resultsWe identified 2995 patients referred with suspected ATTR-CA, of whom 1967 had a diagnosis of ATTR-CA confirmed. Analysis by 5-year periods revealed an incremental increase in referrals, with higher proportions of patients having been referred after bone scintigraphy and cardiac magnetic resonance imaging (2% versus 34% versus 51% versus 55%, chi-square
conclusionsThere has been a substantial increase in ATTR-CA diagnoses, with more patients being referred after local advanced cardiac imaging. Patients are now more often diagnosed at an earlier stage of the disease, with substantially lower mortality. These changes may have important implications for initiation and outcome of therapy and urgently need to be factored into clinical trial design.
Indexed as
Amyloid Neuropathies, FamilialCardiomyopathiesCohort StudiesHumansPrealbuminStroke VolumeVentricular Function, LeftPrealbuminamyloidosisprognosistransthyretin
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
NCT07529860ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.